MCK vs VRTX
McKesson Corporation vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
MCK
McKesson Corporation
65
Buy
VS
VRTX
Vertex Pharmaceuticals
67
Buy
| Metric | MCK | VRTX |
|---|
| AI Score |
65
|
67
|
| Price |
$869.27
|
$496.21
|
| P/E Ratio |
23.17×
|
28.64×
|
| ROE |
-219.2%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
3.6%
|
86.0%
|
| Debt / Equity |
-2.76×
|
0.00×
|
| Dividend Yield |
0.4%
|
0.0%
|
| RSI (14) |
59.0
|
66.6
|
| Beta |
0.315
|
0.292
|
| Expected Upside |
+3.0%
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for MCK versus VRTX.
VRTX leads by 2 points.
VRTX scores 67/100 (Buy) versus MCK at 65/100 (Buy).
MCK Committee View
75% agreement
4 analysts
The primary driver is market regime is bullish (bull market -- normal position sizing). The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 29.0 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical